AZD6738 Clinical Trials

1 actively recruiting trial

No change since May 2026

Pipeline

Phase 2: 1

Top Sponsors

Institute of Cancer Research, United Kingdom1

Indications

HRD1
Triple Negative Breast Cancer (TNBC)1
Breast Neoplasm1
Breast Cancer1
Cancer1

Other1 trial

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.